JP2005505256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505256A5 JP2005505256A5 JP2003502040A JP2003502040A JP2005505256A5 JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5 JP 2003502040 A JP2003502040 A JP 2003502040A JP 2003502040 A JP2003502040 A JP 2003502040A JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- antigen
- binding fragment
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 8
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 3
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 206010061481 Renal injury Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29544901P | 2001-06-01 | 2001-06-01 | |
| US29590701P | 2001-06-04 | 2001-06-04 | |
| PCT/US2002/017402 WO2002098920A1 (en) | 2001-06-01 | 2002-05-31 | Molecules and methods for inhibiting shedding of kim-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010068988A Division JP2010150291A (ja) | 2001-06-01 | 2010-03-24 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005505256A JP2005505256A (ja) | 2005-02-24 |
| JP2005505256A5 true JP2005505256A5 (enExample) | 2006-01-05 |
| JP4527394B2 JP4527394B2 (ja) | 2010-08-18 |
Family
ID=26969139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003502040A Expired - Fee Related JP4527394B2 (ja) | 2001-06-01 | 2002-05-31 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
| JP2010068988A Withdrawn JP2010150291A (ja) | 2001-06-01 | 2010-03-24 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010068988A Withdrawn JP2010150291A (ja) | 2001-06-01 | 2010-03-24 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7041290B2 (enExample) |
| EP (1) | EP1401869B1 (enExample) |
| JP (2) | JP4527394B2 (enExample) |
| AT (1) | ATE382060T1 (enExample) |
| AU (1) | AU2002305785B2 (enExample) |
| CA (1) | CA2448427C (enExample) |
| DE (1) | DE60224275T2 (enExample) |
| DK (1) | DK1401869T3 (enExample) |
| NZ (1) | NZ530457A (enExample) |
| WO (1) | WO2002098920A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997044460A1 (en) * | 1996-05-24 | 1997-11-27 | Biogen, Inc. | Modulators of tissue regeneration |
| AU6986201A (en) * | 2000-06-16 | 2002-01-02 | Biogen Inc | Renal regulatory elements and methods of use thereof |
| WO2002098920A1 (en) * | 2001-06-01 | 2002-12-12 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
| AU2013205381B2 (en) * | 2002-03-19 | 2016-04-14 | Celldex Therapeutics, Inc. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| JP2005535294A (ja) * | 2002-03-19 | 2005-11-24 | キュラジェン コーポレイション | 治療ポリペプチド、それをコードする核酸、および使用方法 |
| DE60322744D1 (de) * | 2002-12-30 | 2008-09-18 | Biogen Idec Inc | Kim-1-antagonisten und verwendung zur immunsystemmodulation |
| AU2013242840B2 (en) * | 2003-03-19 | 2017-01-19 | Amgen Fremont Inc. | Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof |
| CA2519528C (en) * | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| EP1532984A1 (en) * | 2003-11-19 | 2005-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia |
| NZ562045A (en) * | 2005-03-02 | 2010-12-24 | Biogen Idec Inc | Kim-1 antibodies for treatment of TH2-mediated conditions |
| JP2009515897A (ja) | 2005-11-10 | 2009-04-16 | キュラジェン コーポレイション | Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法 |
| KR20110094029A (ko) | 2008-11-10 | 2011-08-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체-관련된 장애를 치료하는 방법 및 조성물 |
| AU2010336392B2 (en) | 2009-12-23 | 2014-01-23 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating kidney disorders in a canine |
| SG182408A1 (en) | 2010-01-11 | 2012-08-30 | Alexion Pharma Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| EP2563813B1 (en) | 2010-04-30 | 2015-08-26 | Alexion Pharmaceuticals, Inc. | Anti-c5a antibodies and methods for using the antibodies |
| CA2826453A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
| US20150110792A1 (en) * | 2011-11-22 | 2015-04-23 | Biogen Idec Ma Inc. | ANTI-TIM-1 Antibodies And Uses Thereof |
| WO2015023836A1 (en) * | 2013-08-16 | 2015-02-19 | The Brigham And Women's Hospital, Inc. | Kim-1 as a therapeutic target in conditions associated with kidney fibrosis |
| US10712349B2 (en) | 2014-04-15 | 2020-07-14 | The Brigham And Women's Hospital, Inc. | Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
| JP7303749B2 (ja) * | 2017-01-13 | 2023-07-05 | セルダラ メディカル、エルエルシー | Ｔｉｍ－１を標的とするキメラ抗原受容体 |
| IL301115A (en) | 2017-04-28 | 2023-05-01 | Acuitas Therapeutics Inc | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| IL322436A (en) | 2018-09-21 | 2025-09-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| CN113474328B (zh) | 2019-01-11 | 2025-07-11 | 爱康泰生治疗公司 | 用于脂质纳米颗粒递送活性剂的脂质 |
| AU2021308681A1 (en) | 2020-07-16 | 2023-03-09 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| CN118647600A (zh) | 2021-12-16 | 2024-09-13 | 爱康泰生治疗公司 | 用于脂质纳米颗粒制剂的脂质 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622861A (en) | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
| WO1997044460A1 (en) | 1996-05-24 | 1997-11-27 | Biogen, Inc. | Modulators of tissue regeneration |
| AU6986201A (en) * | 2000-06-16 | 2002-01-02 | Biogen Inc | Renal regulatory elements and methods of use thereof |
| WO2002098920A1 (en) * | 2001-06-01 | 2002-12-12 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
| US7838220B2 (en) | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
| CN1538853A (zh) | 2001-06-29 | 2004-10-20 | ������˹̹�������ѧ�й�ίԱ�� | T细胞调节基因及其使用方法 |
| WO2003025138A2 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US7687454B2 (en) | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
| US7470428B2 (en) | 2002-01-30 | 2008-12-30 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| JP2005535294A (ja) | 2002-03-19 | 2005-11-24 | キュラジェン コーポレイション | 治療ポリペプチド、それをコードする核酸、および使用方法 |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| CA2519528C (en) | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| US20050119210A1 (en) | 2003-05-20 | 2005-06-02 | Xiaobing Be | Compositions and methods for diagnosing and treating cancers |
-
2002
- 2002-05-31 WO PCT/US2002/017402 patent/WO2002098920A1/en not_active Ceased
- 2002-05-31 JP JP2003502040A patent/JP4527394B2/ja not_active Expired - Fee Related
- 2002-05-31 EP EP02734634A patent/EP1401869B1/en not_active Expired - Lifetime
- 2002-05-31 DK DK02734634T patent/DK1401869T3/da active
- 2002-05-31 NZ NZ530457A patent/NZ530457A/en not_active IP Right Cessation
- 2002-05-31 DE DE60224275T patent/DE60224275T2/de not_active Expired - Lifetime
- 2002-05-31 CA CA2448427A patent/CA2448427C/en not_active Expired - Fee Related
- 2002-05-31 AU AU2002305785A patent/AU2002305785B2/en not_active Ceased
- 2002-05-31 AT AT02734634T patent/ATE382060T1/de not_active IP Right Cessation
-
2003
- 2003-11-20 US US10/718,321 patent/US7041290B2/en not_active Expired - Lifetime
-
2006
- 2006-02-07 US US11/349,852 patent/US7300652B2/en not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/929,289 patent/US7696321B2/en not_active Expired - Lifetime
-
2010
- 2010-03-24 JP JP2010068988A patent/JP2010150291A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505256A5 (enExample) | ||
| JP2005520566A5 (enExample) | ||
| JP2022120070A (ja) | 抗ｃｄ７１抗体、活性化可能抗ｃｄ７１抗体、およびその使用方法 | |
| JP2010535713A5 (enExample) | ||
| JP2004534020A5 (enExample) | ||
| WO2019024911A1 (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| JP2008529497A5 (enExample) | ||
| JP2023081303A5 (enExample) | ||
| JP2010513303A5 (enExample) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2012532851A5 (enExample) | ||
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| JP2009197002A5 (enExample) | ||
| RU2010141584A (ru) | Антитело против csf-1r | |
| JP2017522861A5 (enExample) | ||
| RU2011110405A (ru) | Агенты, связывающие рецептор frizzled и их применение | |
| JP2010533498A5 (enExample) | ||
| JP2004518624A5 (enExample) | ||
| JP2010508847A5 (enExample) | ||
| JP2008529494A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| CA2928895A1 (en) | Antibodies against ccr9 and applications thereof | |
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 |